CTOs on the Move

Nivagen Pharmaceuticals, Inc.

www.nivagen.com

 
Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and over the counter products for the North American market. Our vision is to deliver high quality products at affordable prices by leveraging global partnerships with the best FDA approved manufacturing facilities across the world.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.nivagen.com
  • 3100 Fite Cir Suite 208
    Sacramento, CA USA 95827
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Nivagen Pharmaceuticals, Inc. raised $16M on 05/19/2020

Similar Companies

American Board of Pain Medicine

American Board of Pain Medicine is a Glenview, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ascensia Diabetes Care

Our goal is to provide products and solutions that make a positive, daily difference for people with diabetes. We want to make sure diabetes doesnt get in the way of peoples future, enabling them to live richer lives. At Ascensia Diabetes Care we ...

Genexa

Genexa is the world`s first and only clean medicine company and was recognized in 2022 by Fast Company as the no. 1 Most Innovative Company in Wellness. We were founded in 2016 by two dads who believed medicine should only have the active ingredients you need, and not the artificial fillers you don`t. It`s medicine made clean, because that`s what people deserve. Our headquarters is located in Atlanta, where we strive to put people over everything

Recor Medical

The RADIANCE-HTN Clinical study is a randomized, controlled study to evaluate the Paradise Renal Denervation System intended to treat high blood pressure. The study will be in up to 40 hospitals in 5 countries (US, France, Germany, The Netherlands, UK...

Eupraxia Pharmaceuticals

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.